363 related articles for article (PubMed ID: 33781610)
1. LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease.
Sosero YL; Yu E; Krohn L; Rudakou U; Mufti K; Ruskey JA; Asayesh F; Laurent SB; Spiegelman D; Fahn S; Waters C; Sardi SP; Bandres-Ciga S; Alcalay RN; Gan-Or Z; Senkevich K
Neurobiol Aging; 2021 Jul; 103():142.e1-142.e5. PubMed ID: 33781610
[TBL] [Abstract][Full Text] [Related]
2. Alpha galactosidase A activity in Parkinson's disease.
Alcalay RN; Wolf P; Levy OA; Kang UJ; Waters C; Fahn S; Ford B; Kuo SH; Vanegas N; Shah H; Liong C; Narayan S; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Oliva P; Keutzer J; Marder K; Zhang XK
Neurobiol Dis; 2018 Apr; 112():85-90. PubMed ID: 29369793
[TBL] [Abstract][Full Text] [Related]
3. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
4. The Effect of p.G2019S Mutation in the
Usenko TS; Timofeeva A; Beletskaia M; Basharova K; Baydakova G; Bezrukova A; Grunina M; Emelyanov A; Miliukhina I; Zakharova E; Pchelina S
J Integr Neurosci; 2024 Jan; 23(1):16. PubMed ID: 38287861
[TBL] [Abstract][Full Text] [Related]
5. LRRK2 exonic variants are associated with lysosomal hydrolase activities and lysosphingolipid alterations in Parkinson's disease.
Usenko TS; Senkevich KA; Basharova KS; Bezrukova AI; Baydakova GV; Tyurin AA; Beletskaya MV; Kulabukhova DG; Grunina MN; Emelyanov AK; Miliukhina IV; Timofeeva AA; Zakharova EY; Pchelina SN
Gene; 2023 Oct; 882():147639. PubMed ID: 37473971
[TBL] [Abstract][Full Text] [Related]
6. Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Glinka T; Goldstein O; Kestenbaum M; Cedarbaum JM; Mabrouk OS; Fraser KB; Shirvan JC; Orr-Urtreger A; Mirelman A; Thaler A
Mov Disord; 2022 Jan; 37(1):190-195. PubMed ID: 34550621
[TBL] [Abstract][Full Text] [Related]
7. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
[TBL] [Abstract][Full Text] [Related]
8. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.
von Linstow CU; Gan-Or Z; Brundin P
Transl Neurodegener; 2020 Oct; 9(1):39. PubMed ID: 33066808
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients.
Ysselstein D; Nguyen M; Young TJ; Severino A; Schwake M; Merchant K; Krainc D
Nat Commun; 2019 Dec; 10(1):5570. PubMed ID: 31804465
[TBL] [Abstract][Full Text] [Related]
10. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
Ortega RA; Wang C; Raymond D; Bryant N; Scherzer CR; Thaler A; Alcalay RN; West AB; Mirelman A; Kuras Y; Marder KS; Giladi N; Ozelius LJ; Bressman SB; Saunders-Pullman R
JAMA Netw Open; 2021 Apr; 4(4):e215845. PubMed ID: 33881531
[TBL] [Abstract][Full Text] [Related]
11. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
[TBL] [Abstract][Full Text] [Related]
12. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
13. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
Lee CY; Menozzi E; Chau KY; Schapira AHV
J Neurochem; 2021 Dec; 159(5):826-839. PubMed ID: 34618942
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
15. Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.
Bryant N; Malpeli N; Ziaee J; Blauwendraat C; Liu Z; ; West AB
Hum Mol Genet; 2021 Apr; 30(6):454-466. PubMed ID: 33640967
[TBL] [Abstract][Full Text] [Related]
16. Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line.
Ruz C; Alcantud JL; Vives F; Arrebola F; Hardy J; Lewis PA; Manzoni C; Duran R
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805938
[TBL] [Abstract][Full Text] [Related]
17. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
[TBL] [Abstract][Full Text] [Related]
18. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
[TBL] [Abstract][Full Text] [Related]
19. Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
Ortega RA; Bressman SB; Raymond D; Ozelius LJ; Katsnelson V; Leaver K; Swan MC; Shanker V; Miravite J; Wang C; Bennett SAL; Saunders-Pullman R
Mov Disord; 2022 Nov; 37(11):2217-2225. PubMed ID: 36054306
[TBL] [Abstract][Full Text] [Related]
20. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
